Wed, October 4, 2023

Raghuram Selvaraju Reiterated (URGN) at Strong Buy and Held Target at $54 on, Oct 4th, 2023

Raghuram Selvaraju of HC Wainwright & Co., Reiterated "UroGen Pharma Ltd." (URGN) at Strong Buy and Held Target at $54 on, Oct 4th, 2023.

Raghuram has made no other calls on URGN in the last 4 months.



There is 1 other peer that has a rating on URGN. Out of the 1 peers that are also analyzing URGN, all agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Paul Choi of "Goldman Sachs" Maintained at Hold with Increased Target to $18 on, Monday, July 31st, 2023